EDSA Edesa Biotech Inc

Price (delayed)

$7.18

Market cap

$63.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.34

Enterprise value

$53.84M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 ...

Highlights
Edesa Biotech's EPS has decreased by 17% from the previous quarter but it has increased by 16% YoY
EDSA's net income has dropped by 79% year-on-year and by 34% since the previous quarter
The quick ratio has shrunk by 72% QoQ and by 70% YoY

Key stats

What are the main financial stats of EDSA

EDSA stock price

How has the Edesa Biotech stock price performed over time
Intraday
4.66%
1 week
-8.65%
1 month
-55.43%
1 year
268.21%
YTD
405.63%
QTD
37.28%

Financial performance

How have Edesa Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.01M
Net income
-$10.44M
Gross margin
N/A
Net margin
N/A
EDSA's net income has dropped by 79% year-on-year and by 34% since the previous quarter
Edesa Biotech's operating income has plunged by 70% YoY and by 32% from the previous quarter

Price vs fundamentals

How does EDSA's price correlate with its fundamentals

Growth

What is Edesa Biotech's growth rate over time

Valuation

What is Edesa Biotech stock price valuation
P/E
N/A
P/B
5.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Edesa Biotech's EPS has decreased by 17% from the previous quarter but it has increased by 16% YoY
EDSA's price to book (P/B) is 196% higher than its last 4 quarters average of 1.9 and 76% higher than its 5-year quarterly average of 3.2
The equity has declined by 34% year-on-year and by 27% since the previous quarter

Efficiency

How efficient is Edesa Biotech business performance
The company's return on equity fell by 47% QoQ but it rose by 20% YoY
Edesa Biotech's return on assets has decreased by 44% QoQ but it has increased by 4.2% YoY

Dividends

What is EDSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDSA.

Financial health

How did Edesa Biotech financials performed over time
The total liabilities has soared by 189% since the previous quarter and by 139% year-on-year
The quick ratio has shrunk by 72% QoQ and by 70% YoY
EDSA's debt is 100% smaller than its equity
The equity has declined by 34% year-on-year and by 27% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.